Zacks Investment Research on MSN
MRNA partners with CEPI to develop vaccine for Bundibugyo ebolavirus
Moderna MRNA announced a new collaboration with the Coalition for Epidemic Preparedness Innovations (“CEPI”) to accelerate ...
A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in ...
InvestorsHub on MSN
Moderna joins global initiative to advance vaccine candidate for Bundibugyo Ebola virus (MRNA)
Moderna (NASDAQ:MRNA) announced on Monday a new collaboration with an international health organization aimed at accelerating ...
Under the plans, CEPI has committed up to $50 million to US-based Moderna for preclinical development and Phase 1 clinical ...
A personalized mRNA vaccine may change melanoma treatment, with 70% of patients cancer-free after 5 years. Discover how this ...
The U.S. helped pioneer the technology, but new funding cuts may shift breakthroughs — and industry leadership — overseas.
Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.
After getting slapped with a surprise refuse-to-file letter signed by former CBER Director Vinay Prasad, Moderna’s flu ...
On May 6, 2026, Moderna’s board amended its bylaws to require Securities Act of 1933 lawsuits be filed exclusively in US ...
The mRNA vaccines and therapeutics market is poised for robust growth, driven by expanding applications beyond COVID-19, ...
Scientists from China have developed a new broad-spectrum mRNA vaccine that could provide long-term protection against the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results